+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Fracture risk and bone mineral density reduction associated with proton pump inhibitors

Fracture risk and bone mineral density reduction associated with proton pump inhibitors

PharmacoTherapy 32(1): 67-79

Many patients receive prolonged proton pump inhibitor (PPI) therapy for upper gastrointestinal disorders, but the long-term safety of PPIs, particularly increased risk of hip and nonhip fractures, has been questioned. To summarize the current literature on the risk of bone mineral density (BMD) reduction and fracture associated with PPI therapy, we conducted a literature search to identify all pertinent studies from 1980-February 2011. A total of 14 observational studies were included in this review. Most studies evaluated the risk of fracture associated with prolonged PPI exposure. Eight studies found an increased fracture risk at the hip, and five studies found an increased fracture risk at the spine associated with PPIs. Three studies showed reduction in fracture risk associated with PPIs after discontinuation for 1 month-1 year. Three studies evaluated the risk of BMD reduction associated with PPIs but did not find consistent changes in baseline or subsequent BMD. The current data suggest a modest increase in the risk of hip fracture and vertebral fracture associated with PPIs, although some studies showed conflicting results. Further studies will be needed to determine whether the increased risk of fracture is due to PPI exposure or residual confounding.

(PDF emailed within 0-6 h: $19.90)

Accession: 053295477

Download citation: RISBibTeXText

PMID: 22392829

DOI: 10.1002/PHAR.1007

Related references

Proton pump inhibitors use and change in bone mineral density. International Journal of Rheumatic Diseases 19(9): 864-868, 2017

Bone up on proton pump inhibitors and fracture risk. Nursing 37(10): 60-61, 2007

Contribution of bone mineral density and bone markers to the estimation of fracture risk and to the fracture risk reduction with antiresorptive agents. Journal of Musculoskeletal & Neuronal Interactions 4(1): 48-49, 2004

Correlation of Bone Mineral Density Scores and Proton Pump Inhibitors Use in the Elderly. Current Rheumatology Reviews 12(2): 162-166, 2017

Effect of long-term proton pump inhibitors on bone mineral density. La Tunisie Medicale 96(3): 193-197, 2018

Role of proton pump inhibitors in calcium absorption, bone resorption, and risk of hip fracture. Journal of Pharmacy Technology 23(5): 275-280, 2007

Proton pump inhibitors and fracture: they impair bone quality and increase fall risk?. Osteoporosis International 27(4): 1675-1676, 2016

Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors. Biomedical Reports 5(2): 165-170, 2016

Proton pump inhibitors do not induce change in bone mineral density in a long-term observational study. Evidence-Based Medicine 18(5): 192-193, 2014

Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study. Journal of Bone and Mineral Research 30(2): 232-239, 2016

Is bone mineral density predictive of fracture risk reduction?. Current Medical Research and Opinion 20(3): 341-349, 2004

Changes in bone mineral density, bone turnover markers, and vertebral fracture risk reduction with once weekly teriparatide. Current Medical Research and Opinion 30(5): 931-936, 2014

Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Archives of Internal Medicine 170(9): 765-771, 2010

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. Journal of Clinical Densitometry 7(3): 255-261, 2004

Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. Journal of Clinical Endocrinology and Metabolism 92(8): 3076-3081, 2007